← Back to Screener
Altimmune, Inc. Common Stock (ALT)
Price$3.56
Favorite Metrics
Price vs S&P 500 (26W)-17.89%
Price vs S&P 500 (4W)-4.65%
Market Capitalization$463.05M
All Metrics
Book Value / Share (Quarterly)$2.03
P/TBV (Annual)3.11x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-83.45%
Cash Flow / Share (Quarterly)$-0.61
Price vs S&P 500 (YTD)-5.32%
Net Profit Margin (TTM)-214860.98%
EPS (TTM)$-1.00
10-Day Avg Trading Volume2.15M
EPS Excl Extra (TTM)$-1.00
Revenue Growth (5Y)-65.33%
EPS (Annual)$-1.00
ROI (Annual)-33.99%
Gross Margin (Annual)100.47%
Net Profit Margin (5Y Avg)-142743.71%
Cash / Share (Quarterly)$2.47
Revenue Growth QoQ (YoY)420.00%
ROA (Last FY)-31.47%
Revenue Growth TTM (YoY)105.00%
EBITD / Share (TTM)$-1.07
ROE (5Y Avg)-51.24%
Operating Margin (TTM)-230460.98%
Cash Flow / Share (Annual)$-0.61
P/B Ratio2.06x
P/B Ratio (Quarterly)1.67x
Net Income / Employee (Annual)$-2
EV / Revenue (TTM)11062.83x
Net Interest Coverage (TTM)-15.42x
ROA (TTM)-41.65%
EPS Incl Extra (Annual)$-1.00
Current Ratio (Annual)18.55x
Quick Ratio (Quarterly)18.35x
3-Month Avg Trading Volume4.33M
52-Week Price Return-21.76%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.75
P/S Ratio (Annual)11293.88x
Asset Turnover (Annual)0.00x
52-Week High$7.73
Operating Margin (5Y Avg)-154341.23%
EPS Excl Extra (Annual)$-1.00
CapEx CAGR (5Y)-49.65%
Tangible BV CAGR (5Y)41.27%
26-Week Price Return-11.00%
Quick Ratio (Annual)18.35x
13-Week Price Return-16.04%
Total Debt / Equity (Annual)0.15x
Current Ratio (Quarterly)18.55x
Enterprise Value$453.576
Revenue / Share Growth (5Y)-72.53%
Asset Turnover (TTM)0.00x
Book Value / Share Growth (5Y)-19.74%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-216521.95%
Cash / Share (Annual)$2.47
3-Month Return Std Dev82.31%
Net Income / Employee (TTM)$-2
ROE (Last FY)-39.17%
Net Interest Coverage (Annual)-881.33x
EPS Basic Excl Extra (Annual)$-1.00
P/FCF (TTM)2572.49x
Receivables Turnover (TTM)0.05x
Total Debt / Equity (Quarterly)0.15x
EPS Incl Extra (TTM)$-1.00
Receivables Turnover (Annual)0.05x
ROI (TTM)-45.35%
P/S Ratio (TTM)11293.88x
Pretax Margin (5Y Avg)-143089.14%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.75
Price vs S&P 500 (52W)-56.39%
Year-to-Date Return-1.39%
5-Day Price Return8.21%
EPS Normalized (Annual)$-1.00
ROA (5Y Avg)-45.40%
Net Profit Margin (Annual)-214860.98%
Month-to-Date Return15.58%
EBITD / Share (Annual)$-1.07
Operating Margin (Annual)-230460.98%
LT Debt / Equity (Annual)0.15x
ROI (5Y Avg)-50.20%
LT Debt / Equity (Quarterly)0.15x
EPS Basic Excl Extra (TTM)$-1.00
P/TBV (Quarterly)3.11x
P/B Ratio (Annual)1.67x
Pretax Margin (TTM)-216521.95%
Book Value / Share (Annual)$2.03
Price vs S&P 500 (13W)-18.42%
Beta0.38x
P/FCF (Annual)841.91x
Revenue / Share (TTM)$0.00
ROE (TTM)-49.35%
52-Week Low$2.87
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.93
3.93
3.93
3.93
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALTAltimmune, Inc. Common Stock | 11293.88x | 105.00% | — | — | $3.56 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Altimmune is a clinical-stage biopharmaceutical company developing therapies for serious liver diseases. Its lead candidate, pemvidutide, is a dual GLP-1/glucagon receptor agonist in late-stage development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The balanced 1:1 dual-receptor mechanism differentiates pemvidutide within the metabolic disease space, with the company exploring additional indications to expand its addressable market.